News/Events

Takafumi Ochiai (Partner)’s comment was quoted in an article entitled "No Objection to the Classification of Drugs Requiring Supervision Not Shifting to OTC Use," in the Nikkei Medical, dated August 10, 2023.

“Business, Legal Affairs and Intellectual Property Rapidly Changing along with ChatGPT and Generative AI”: Fumiaki Matsuoka (Partner)

“Cybersecurity Response upon the Occurrence of an Incident and During Peacetime”: Fumiaki Matsuoka (Partner)

David Tan has been promoted to the position of Partner at the Firm as of August 1, 2023.

Hideaki Yamagami, an attorney admitted in Japan, became an adviser of Atsumi & Sakai on August 1, 2023. Tomotaka Tokuno, an attorney admitted in Japan, joined Atsumi & Sakai on August 1, 2023, as Of Counsel.

Atsumi & Sakai has received high evaluation in the IFLR1000 2023

Articles on the NIKKEI Generative AI Symposium were published in the Nikkei BizGate: Hiroyuki Sanbe (Partner)

Kenichi Tanizaki became a Tokyo Region Mediator of the Non-Profit Organization, Financial Instruments Mediation Assistance Center as of July, 2023.

“How to Respond to 'ChatGPT Generative AI' that Brings Radical Business Transformation”: Fumiaki Matsuoka (Partner)

“How to Deal with the '2024 Labor Problem'”: Haruhiko Sasaki (Associate)